信会师报字[2025]第 ZA12079 号 广州金域医学检验集团股份有限公司 内部控制审计报告 2024 年度 内部控制审计报告 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内部控制审计报告 第 1 页 四、财务报告内部控制审计意见 我们认为，贵公司于 2024 年 12 月 31 日按照《企业内部控制基 本规范》和相关规定在所有重大方面保持了有效的财务报告内部控 制。 广州金域医学检验集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了广州金域医学检验集团股份有限公司（以下简称 贵公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是贵公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计 ...

Product Innovation and Development - In 2024, the company achieved significant results in product innovation and service enhancement, focusing on high-sensitivity testing products and integrated solutions for complex diseases [3]. - The company launched the first large model in the medical testing industry, "Yujian Yiyan," and successfully integrated it with DEEPSEEK, showcasing advancements in AI technology application [4]. - The company launched several innovative products, including a high-sensitivity detection product for colorectal cancer and a PNH clone detection scheme with a sensitivity of 99.9% [47]. - The company developed a cost-effective early screening project for Alzheimer's disease, targeting a larger elderly population [47]. - The company has developed over 90 types of medical testing and AI technologies, enhancing the sensitivity of autoimmune brain antibody detection from 78% to 95% [84]. - The company achieved a 2.94% year-on-year increase in specimen testing volume, maintaining a leading market share [75]. - The company has established a product system covering "full lifecycle, all disease areas, and all diagnosis and treatment processes" [85]. Financial Performance - The company reported a significant increase in revenue, reaching $1.5 billion, representing a 20% year-over-year growth [22]. - The company reported a revenue increase of 15% year-over-year, reaching 1.2 billion RMB in the last quarter [20]. - The company achieved a revenue of ¥7,189,544,739.91, a decrease of 15.81% year-on-year, and a net profit attributable to shareholders of -¥381,241,138.69, a decrease of 159.26% year-on-year [91]. - The company provided a future outlook with a revenue guidance of 1.5 billion RMB for the next quarter, representing a 25% increase [20]. - The company reported a significant increase in user data, with a year-over-year growth of 25% in active users [142]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 20% to 1.8 billion yuan [140]. Market Expansion and Strategy - The company is expanding its market presence with plans to open 10 new laboratories across major cities in China by the end of the year [20]. - Market expansion plans include entering three new countries by the end of the fiscal year, targeting a 15% increase in international sales [23]. - The company is actively pursuing digital transformation to build a "Medical Testing 4.0" system, focusing on data-driven new productivity [61]. - The company is considering strategic acquisitions to enhance its market position, with a budget of $100 million earmarked for potential deals [137]. - The company is exploring new business models through data monetization and predictive disease modeling, aiming to create new value points in the industry [117]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 15% through efficiency improvements in logistics and supply chain management [20]. - The company achieved a gross margin of 60%, an increase from 55% in the previous quarter, indicating improved operational efficiency [22]. - The company is focused on enhancing its governance framework, as shown by the revisions to its articles of association and meeting rules [132]. - The company plans to enhance operational efficiency through a centralized management system and advanced tools, aiming for automated and intelligent production [120]. - The company has set a goal to improve operational efficiency, targeting a 10% reduction in costs by the end of the fiscal year [137]. Customer Engagement and Satisfaction - The registered users of the one-stop customer service platform KMC exceeded 570,000, indicating strong user engagement and service adoption [4]. - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of new service strategies implemented [21]. - The company upgraded its customer service system, focusing on standardization, differentiation, and intelligent capabilities to enhance service efficiency and quality [49]. Research and Development - Investment in R&D increased by 30%, focusing on innovative testing technologies and services [21]. - The company is investing $50 million in R&D for new technologies aimed at enhancing diagnostic capabilities [22]. - The company has a data platform managing over 23 PB of medical big data, with a growth rate of 1 PB per year, providing a competitive advantage in data service [87]. - The company has established a high-quality talent pool through various training programs, adding 1,190 new courses in 2024, including 1,005 online courses [90]. Corporate Governance and Shareholder Engagement - The company held three shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority investors [128]. - The board of directors convened nine meetings to review major company matters, enhancing governance and decision-making processes [128]. - The company approved several resolutions in its annual general meeting, including financial reports and profit distribution plans for 2023 [131]. - The company has undergone changes in its board and management structure, with new appointments effective from September 27, 2024, indicating a strategic refresh [135]. Social Responsibility and Public Welfare - The company has engaged in public welfare activities across over 20 provinces, benefiting approximately 10,000 individuals through cancer early screening initiatives [5]. - The company invested a total of CNY 28.72 million in social responsibility projects, including CNY 20.64 million in cash donations and CNY 8.07 million in material support [193]. - The company constructed 182 medical laboratories across 140 poverty-stricken counties, investing 11.6681 million yuan to enhance local medical testing and pathology services [195]. - The company actively participated in initiatives like "Thousand Enterprises Helping Thousand Towns" and "Guangzhou Private Enterprises Supporting Rural Revitalization" in key areas of Guizhou Province [196].

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,466,504,705.88, a decrease of 20.35% compared to the same period last year[6] - The net profit attributable to shareholders was -¥27,785,254.88, representing a decline of 49.09% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥38,700,504.33, down 32.11% year-on-year[6] - The basic and diluted earnings per share were both -¥0.06, a decrease of 50.00% year-on-year[6] - Net profit for Q1 2025 was a loss of ¥34,725,978.18, compared to a loss of ¥26,419,413.39 in Q1 2024, representing a 31.5% increase in losses[30] - The total comprehensive income for Q1 2025 was a loss of ¥36,660,342.17, compared to a loss of ¥26,338,875.79 in Q1 2024[31] Cash Flow - The net cash flow from operating activities was ¥54,504,692.15, a significant increase of 139.41% compared to the previous year[6] - The net cash flow from operating activities for Q1 2025 was ¥54,504,692.15, a significant improvement from a negative cash flow of ¥138,310,819.32 in Q1 2024[36] - The net cash flow from investing activities was -97,426,897.49, compared to -97,210,373.11 in the previous period, indicating a slight increase in cash outflow[37] - Cash inflow from financing activities totaled 27,458,021.55, down from 65,159,738.92, reflecting a significant decrease of approximately 58%[37] - Cash outflow for financing activities was 429,632,269.24, compared to 174,788,077.20 in the previous period, representing an increase of about 145%[37] - The net cash flow from financing activities was -402,174,247.69, worsening from -109,628,338.28 in the previous period[37] - The impact of exchange rate changes on cash and cash equivalents was -1,510,271.71, contrasting with a positive impact of 203,344.80 previously[37] - The net increase in cash and cash equivalents was -446,606,724.74, compared to -344,946,185.91 in the previous period, indicating a larger decline[37] - The ending balance of cash and cash equivalents was 1,975,917,824.88, down from 2,104,727,955.32, reflecting a decrease of approximately 6%[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,854,909,916.16, a decrease of 5.17% from the end of the previous year[6] - The company's current assets totaled ¥6,818,528,334.74, down from ¥7,318,237,550.29, indicating a decrease of about 6.86%[22] - The cash and cash equivalents decreased to ¥1,987,068,521.84 from ¥2,433,585,245.93, reflecting a decline of approximately 18.36%[21] - Accounts receivable stood at ¥4,321,276,982.00, slightly down from ¥4,396,328,960.56, showing a decrease of about 1.70%[21] - The total liabilities decreased to ¥2,837,464,947.26 from ¥2,916,821,149.44, which is a reduction of approximately 2.71%[24] - The company's non-current liabilities totaled ¥690,242,205.53, a slight increase from ¥684,406,029.88, indicating a rise of about 0.12%[24] - The total equity remained stable at ¥7,017,444,968.90, unchanged from the previous period[24] - The total equity attributable to shareholders of the parent company decreased to ¥6,887,883,046.28 from ¥7,325,269,947.15, reflecting a decline of 6.0%[25] - As of March 31, 2025, the total assets of the company amounted to ¥9,854,909,916.16, a decrease from ¥10,391,893,742.49 as of December 31, 2024, representing a decline of approximately 5.14%[21] Operational Efficiency and Strategy - The gross profit margin increased by 1.16 percentage points compared to the previous year[7] - The company is focusing on long-term development through differentiated services and cost leadership strategies to enhance competitiveness[7] - The company aims to improve operational efficiency through digital transformation and automation in production processes[7] - Research and development expenses for Q1 2025 were ¥77,105,975.66, down 16.3% from ¥92,123,715.26 in Q1 2024[29] - The company has invested ¥4,236,639.48 in development expenditures, up from ¥3,354,408.43, indicating an increase of about 26.19%[23] - The company’s goodwill remained constant at ¥52,205,371.01, with no change from the previous reporting period[23] Accounting Standards - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[38]

证券代码：603882 证券简称：金域医学公告编号：2025-016 广州金域医学检验集团股份有限公司 二、董事会会议审议情况 广州金域医学检验集团股份有限公司董事会 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票表决方式通过以下决议： （一）审议通过《广州金域医学检验集团股份有限公司市值管理制度》 经审议，为加强公司市值管理工作，进一步规范公司市值管理行为，维护公司、投资者及其他利益相关 者的合法权益，董事会同意公司依据《中华人民共和国公司法》、《中华人民共和国证券法》、《上海 证券交易所股票上市规则》、《上市公司监管指引第10号一一市值管理》及其他法律、法规及规范性文 件的规定，制定《广州金域医学检验集团股份有限公司市值管理制度》。 表决结果：9 票同意，占公司全体董事人数的100%，0票反对，0票弃权。 特此公告。 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第五次会议于2025 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-016 （一）审议通过《广州金域医学检验集团股份有限公司市值管理制度》 经审议，为加强公司市值管理工作，进一步规范公司市值管理行为，维护公 司、投资者及其他利益相关者的合法权益，董事会同意公司依据《中华人民共和 国公司法》、《中华人民共和国证券法》、《上海证券交易所股票上市规则》、《上市 公司监管指引第 10 号——市值管理》及其他法律、法规及规范性文件的规定， 制定《广州金域医学检验集团股份有限公司市值管理制度》。 表决结果：9 票同意，占公司全体董事人数的 100%，0 票反对，0 票弃权。 广州金域医学检验集团股份有限公司 第四届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第 五次会议于 2025 年 4 月 17 日以通讯方式召开，会议通知已于 2025 年 4 月 10 日以电子形式发出。会议由董事长梁耀铭先生主持，本次会议应出席董事 9 ...

重要内容提示: 公司控股股东、实际控制人梁耀铭先生直接持有公司股份 74,191,907 股，占公司总股本的 16.02%。本次解除质押股份 6,550,000 股，占梁耀铭先生 直接持有公司股份数的 8.83%，占公司总股本的 1.41%。 本次股份解除质押后，公司控股股东、实际控制人梁耀铭先生及其一致 行动人严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及 锐致累计质押 31,580,000 股，占其持有公司股份总数的 19.14%，占公司总股本 的 6.82%。 一、上市公司股份解除质押 广州金域医学检验集团股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日接到公司控股股东、实际控制人梁耀铭先生通知，获悉其质押给中信证券股份 有限公司的部分公司股份已办理解除质押手续，具体事项如下： | 股东名称 | 梁耀铭 | | --- | --- | | 本次解除质押股份（股） | 6,550,000 | | 占其所持股份比例 | 8.83% | | 占公司总股本比例 | 1.41% | | 解除质押时间 | 2025 年 4 月 7 日 | | 持股数量（股） | 74,191,90 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-014 广州金域医学检验集团股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 公司控股股东、实际控制人梁耀铭先生直接持有公司股份74,191,907股，占公司总股本的16.02%。本 次质押股份7,000,000股，占梁耀铭先生直接持有公司股份数的9.43%，占公司总股本的1.51%。 ● 本次股份质押后，公司控股股东、实际控制人梁耀铭先生及其一致行动人严婷女士、曾湛文先生以及 梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及锐致累计质押38,130,000股，占其持有公司股份总数的 23.11%，占公司总股本的8.23%。 一、上市公司股份质押 广州金域医学检验集团股份有限公司（以下简称"公司"）于2025年4月3日接到公司控股股东、实际控制 人梁耀铭先生通知，获悉梁耀铭先生所持有本公司的部分股份被质押。具体事项如下： 1.本次股份质押基本情况 ■ 2025年4月4日 广州金域医学检验集团股份有 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-014 广州金域医学检验集团股份有限公司 关于控股股东、实际控制人部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东、实际控制人梁耀铭先生直接持有公司股份 74,191,907 股， 占公司总股本的 16.02%。本次质押股份 7,000,000 股，占梁耀铭先生直接持有 公司股份数的 9.43%，占公司总股本的 1.51%。 本次股份质押后，公司控股股东、实际控制人梁耀铭先生及其一致行动人 严婷女士、曾湛文先生以及梁耀铭先生控制的圣域钫、鑫镘域、圣铂域及锐致 累计质押 38,130,000 股，占其持有公司股份总数的 23.11%，占公司总股本的 8.23%。 一、上市公司股份质押 广州金域医学检验集团股份有限公司（以下简称"公司"）于 2025 年 4 月 3 日接到公司控股股东、实际控制人梁耀铭先生通知，获悉梁耀铭先生所持有本公 司的部分股份被质押。具体事项如下： 2.本次质押股份不涉及被用作重大资产重组业绩补偿 ...

[Table_Page] 公司深度研究|医疗服务 证券研究报告 | [Table_Title] 金域医学（603882.SH） | | --- | 数据资产价值重估，AI 技术驱动创新应用 场景拓展 [Table_Summary] 核心观点： | 基本数据 [Table_BaseInfo] | | | --- | --- | | 总股本/流通股本（百万股） | 463.26/460.13 | | 总市值/流通市值（百万元） | 14856.69/14756.52 | | 一年内最高/最低（元） | 56.05/24.44 | | 30 日日均成交量/成交额（百万） | 13.42/479.51 | | 近 3 个月/6 个月涨跌幅（%） | 21.92/-17.83 | [Table_PicQuote] 相对市场表现 -60% -44% -28% -12% 4% 20% 04/24 05/24 07/24 09/24 11/24 01/25 03/25 金域医学 沪深300 | [分析师： Table_Author]罗佳荣 | | | --- | --- | | | SAC 执证号：S026051609000 ...

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].